Oral Erythromycin in the Treatment of Early Syphilis**From the Department of Dermatology and Syphilology, Baylor University College of Medicine, Houston, Texas.Supported by Grants from Abbott Laboratories, North Chicago, Illinois, and Eli Lilly and Company, Indianapolis, Indiana.  by Brittain Moore, M. et al.
ORAL ERYTHROMYCIN IN THE TREATMENT OF EARLY SYPHILIS*
M. BRITTAIN MOORE, JR., M.D., E. M. VANDERSTOEP, M.D., JOHN M. KNOX, M.D.
AND C. HUNTER MONTGOMERY, M.D.
Erythromycin, an antibiotic with a relatively
narrow activity spectrum similar to penicillin, is
produced by Streptomyces erythreus originally
isolated from a soil sample collected in the Philip-
pines. In 1953 Keller and Morton (1) found
treponemes of the Kazan, Nichols, and Reiter
strains highly susceptible to the action of erythro-
mycin in vitro. The following year Turner and
Schaeffer (2) compared the antitreponemal ac-
tivity of penicillin in experimental rabbit syphilis
with chlortetracycline (I.V.), oxytetracycline
(I.V. and I.M.), chloramphenicol (I.M.), strepto-
mycin (I.M.), erythromycin (I.M.), and magna-
mycin (I.M.). These authors found definite
antitreponemal activity with each drug tested,
but in each case this activity was considerably
less than that of penicillin. The following order of
effectiveness was suggested: 1) penicillin, 2)
magnamycin and erythromycin, 3) oxytetra-
cyeline and chlortetracycline, 4) chloramphenicol
and streptomycin.
Noting the increasing problem of penicillin
allergy, in 1955 Kolmer (3) compared nine differ-
ent antibiotics with penicillin in the treatment of
acute innoculation syphilitic orchitis of rabbits
with the hope of discovering the most effective
alternate antibiotics for clinical trial in human
syphilis. Koimer's study, also an evaluation of
parenteral therapy, employed intramuscular ad-
ministration of the tested drugs once daily for
ten days. His results differed from the earlier
report of Turner and Schaeffer with oxytetracy-
dine showing results comparable to penicillin
when given at a dose of 5 mg/kg body weight.
Similar results could be obtained with tetra-
cycline at 10 mg/kg and chlortetracycline, baci-
tracin, magnamycin and erythromycin at a dos-
age level of 20 mg/kg I,M. daily for a period of
ten days. Chioramphenicol was found least
effective by this author, requiring 80 mg/kg for
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a minimal curative dose in early experimental
rabbit syphilis.
In the present report the available data on
three different treatment schedules for the treat-
ment of early syphilis with erythromycin
propionate are presented. The paper summarizes
the results obtained in treating 130 darkfield
positive cases of primary and secondary syphilis
to whom one of the following oral erythromycin
treatment schedules was given:
(1) Erythromycin propionate* 250 mg. q.i.d.
for 10 days
(2) Erythromycin propionate 500 mg. q.i.d.
for 10 days
(3) Erythromycin propionate 500 mg. t.i.d. for
10 days
Preliminary results with schedules No. 1 and
No. 2 were reported earlier (5). The series has
now been enlarged by increasing the number of
patients on these schedules and extending their
follow-up. Also, a 15 gram—lO day schedule was
added. This study is being pursued in an attempt
to demonstrate the minimal dosage of erythro-
mycin that will yield a satisfactory cure rate for
the growing population of individuals hypersensi-
tive to penicillin.
METHOD
Patients seen in the Houston Social Hygiene
Clinic with dark-field positive syphilis were
screened by the interviewer immediately after
diagnosis before being accepted into the study. An
attempt was made at this time to evaluate the pa-
tient's ability to follow directions and willingness
to cooperate by returning for follow-up examina-
tions. After completion of therapy all patients
were reinterviewed and questioned to determine if
the drug had been taken as directed. In addition,
patients were asked if side effects had occurred.
Follow-up program included monthly clinical and
serologic examinations with a lumbar puncture at
12 months post treatment. For many reasons the
planned follow-up was not achieved in each case.
With presently available diagnostic technics it
is futile to attempt to distinguish between relapse
and reinfection; therefore, no attempt was made to
do so during this investigation. All patients re-
* Ilosone, furnished by Eli Lilly and Company,
Indianapolis, Indiana.
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quiring retreatment are labeled as treatment
failures.
RESULTS
In the 130 patients treated with erythromyein
propionate there have been 6 treatment failures.
These failures occurred within the first 6 months
of follow-up in 5 out of the 6 eases. The sixth case
was discovered at 12 months in the 20 gram—lO
day schedule group after an 8-month lapse in
observations. Several post-treatment lumbar
puntures have been performed in each group
with no abnormalities discovered to date.
1. Ten grams of erythromycin given over a
ten-day period.
Of 35 patients followed from 1—14 months with
erythromycin propionate 250 mg. q.i.d. for 10
days, treatment failures were found in three eases.
These failures were discovered at 2, 3, and 6
months respectively. Twenty-one of the 35 pa-
tients had adequate follow-up examinations for 6
months or longer. Fourteen of the 35 patients
were followed for 9 months or longer. A 14%
treatment failure rate is noted at 6 months (3 out
of 21) and 21% treatment failures at 9 months
(3 out of 14) in those followed for this period. The
data also were evaluated by a modified life table
TABLE I
Ten-gram schedule of erythromycin pro pionate in
early syphilis
Time Followed No. ofPatients
No. of
Failures
Per Cent
of
Failures
6 months or longer
9 months or longer
21
14
3
3
14
21
Modified Life Table Method
Time Followed In Months
AdjustedTotal
No. of
Patients
No. of
Failures
Cumula-
tive Re-
treatment
%
1
2
3
4
5
6
7
8
9
10
11
12
35.0
32.0
28.9
25.7
21.4
20.3
15.8
15.8
12.4
9.0
7.9
5.6
0
1
1
0
0
1
0
0
0
0
0
0
0.0
3.1
6.7
6.7
6.7
11.6
11.6
11.6
11.6
11.6
11.6
11.6
TABLE II
Twenty-gram schedule of erythromycin propionafe
in early syphilis
No. ofTime Followed Patients
No. of
Failures
Per Cent
of
Failures
6 months or longer
9 months or longer
21
15
2
2
10
13
Modified Life Table Method
Time Followed In Months
Adjusted
Total
No. of
Patients
No. of
Failures
Cumula-
tive Re-
treatment
%
1
2
3
4
5
6
7
8
9
10
11
12
34.0 0
32.0 0
31.0 1
26.9 0
24.8 0
20.6 0
17.5 0
16.5 0
14.4 0
12.4 0
7.2 0
7.2 1
0.0
0.0
3.2
3.2
3.2
3.2
3.2
3.2
3.2
3.2
3.2
17.1
method designed to make adjustments for the
progressive loss of patients from observation. *
This showed a cumulative per cent retreatment of
11.6 at 6 and 9 months. Lumbar punctures were
performed on 5 patients in this group at the end
of one year and the findings revealed normal cells
and protein and a nonreactive VDRL in every
instance (Table I).
2. Twenty grams of crythromycin given over
a ten-day period.
Of 34 patients followed from 1—13 months with
erythromycin propionate 500 mg. q.i.d. for 10
days, one treatment failure was seen at 3 months
and another at 12 months. It should be mentioned
that the latter patient had been lost to follow-up
for 8 months after an initial excellent clinical
and serologic response to treatment of secondary
syphilis. A 10% failure rate is noted in 21 of 34
patients followed 6 months or longer (2 of 21)
and a 13% failure rate in the 15 patients followed
9 months or longer (2 of 15). The modified life
table method revealed a cumulative per cent re-
treatment of 3.2 at 6 and 9 months. This was
* Iskrant, A. P., Bowman, II. W., and Donohue,J. F.: Techniques in Evaluation of Rapid Anti-
syphilitic Therapy (Method 1), Public Health
Reports, 63: 965—977, 1948.
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TABLE III
Fifteen-gram schedule of erythromycin pro pionate
in early syphilis
Time Followed No. ofPatients
No. of
Failores
Per Cent
of
Failores
6 months or longer
9 months or longer
24
13
1
1
4
8
Modified Life Table Method
Time Followed In Mooths
Adlosted
Total
No. of
Patients
No. of
Failores
Cumola-
tive Re-
treatmeot
%
1
2
3
4
5
6
7
8
9
10
11
12
61.0
51.0
45.0
38.9
30.7
23.5
19.5
18.4
12.3
9.2
7.2
5.1
0
0
1
0
0
0
0
0
0
0
0
0
0.0
0.0
2.2
2.2
2.2
2.2
2.2
2.2
2.2
2.2
2.2
2.2
raised to 17.1% at 12 months, however, when the
previously discussed delinquent patient was re-
turned to follow-up. Lumbar punctures performed
in 7 patients in this group followed 12 months or
longer revealed normal CSF in each instance
(Table II).
3. Fifteen grams of erythromyein given over a
ten-day period.
Sixty-one patients treated with erythromyein
propionate 500 mg. t.i.d. for 10 days have been
followed for 1—15 months. To date only one treat-
ment failure has been found and this was at 3
months. Twenty-four of the 61 patients have had
adequate follow-up for 6 months or longer on this
schedule with a 4% failure rate (1 of 24). Thir-
teen patients in this group have been followed 9
months or longer with an 8% failure rate (1 of 13).
Again employing the modified life table method a
cumulative per cent retreatment of 2.2 was re-
corded at 6 and 9 months. Lumbar punctures
performed on 5 patients followed 12 months re-
vealed normal CSF in every instance (Table III).
COMMENT
An attempt to discover the minimal dosage of
erythromycin propionate satisfactory for general
use as an alternate antibiotic for the treatment of
penicillin sensitive patients with early syphilis
has been broadened to include a 15 gram—lO day
schedule. Despite attempts at patient orientation
by the clinician and interviewer concerning the
importance of careful follow-up monthly examina-
tions, the percentage of patients adequately
followed after treatment was far from ideal.
Nevertheless, a significant number of patients
have now been accumulated and the results sug-
gest that erythromyein propionate in a dosage of
500 mg. t.i.d. for 10 days is adequate therapy for
primary and secondary syphilis. It is planned to
continue following these patients for a total of 2
years post treatment.
Earlier studies from the Houston Social
Hygiene Clinic relating to the treatment of dark-
field-positive primary and secondary syphilis
with oral erythromyein (4, 5) have resulted in the
following schedules being discarded as probably
inadequate:
Erythromycin stearate 750 mg. q.i.d. for 3 days
Erythromyein stearate 500 mg. q.i.d. for 5 days
Erythromyein stearate 250 mg. q.i.d. for 10
days
To these probably inadequate schedules
erythromyein propionate 250 mg. q.i.d. for 10
days is added at this time.
It is hoped that attempts will be made by other
investigators to establish an optimal minimal
dosage of erythromyein. Also erythromyein and
other alternate antibiotics should be carefully
evaluated in the treatment of all stages of syphilis.
In addition to the proven good antibacterial
activity of erythromyein in a narrower spectrum
than ehloramphenicol or the tetraeyelines, re-
ported side effects with this drug have been
definitely fewer and less severe than with most of
the broader spectrum antibiotics. In none of our
reported erythrnmyein series, covering 213 pa-
tients, have side effects to the therapeutic agent
been a problem or resulted in the discontinuation
of treatment. Ninety-three per cent of the eases
reported in this study allegedly took their medica-
tion for a full 10 days. The remaining patients
were in two smaller groups, receiving the drug
for only 3—5 days.
5UMMAEY
In an earlier report from this Clinic it was
noted that 20 grams of either erythromyein
propionate or erythromyein stearate* adminis-
* Erythroein, furnished by Abbott Labora-
tories, North Chicago, Illinois.
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tered orally over a 10-day period was probably
satisfactory in the treatment of primary and
secondary syphilis.
In this report further evidence is given to sup-
port the effectiveness of the 20-gram erythro-
mycin propionate schedule. An additional series
of patients treated with a 15-gram schedule
(erythromycin propionate 500 mg. t.i.d. for 10
days) is presented and discussed. The latter
schedule has yielded only one treatment failure
in the 13 patients followed a minimum of 9
months.
On the basis of these preliminary observations,
it is felt that erythromycin propionate in the 15-
gram schedule gives results equal to the 20-gram
schedules. Either the 15 or 20 gram treatment
plan should prove satisfactory for early syphilis.
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